AMI Asset Management Corp Sells 7,702 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

AMI Asset Management Corp trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,944 shares of the biopharmaceutical company’s stock after selling 7,702 shares during the period. AMI Asset Management Corp’s holdings in Halozyme Therapeutics were worth $2,802,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Whittier Trust Co. bought a new position in shares of Halozyme Therapeutics in the first quarter worth about $27,000. GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $49,000. Finally, Fidelis Capital Partners LLC bought a new position in Halozyme Therapeutics in the first quarter worth approximately $52,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total value of $617,500.00. Following the sale, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $10,384,868. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total transaction of $617,500.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at $10,384,868. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 89,881 shares of company stock valued at $5,169,834. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.4 %

NASDAQ HALO opened at $50.64 on Wednesday. The stock has a market cap of $6.45 billion, a P/E ratio of 20.93, a P/E/G ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 12-month low of $33.07 and a 12-month high of $65.53. The company has a fifty day simple moving average of $57.56 and a two-hundred day simple moving average of $51.83. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same quarter last year, the company earned $0.68 EPS. The business’s revenue was up 4.7% on a year-over-year basis. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on HALO shares. TD Cowen upped their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Benchmark reiterated a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Morgan Stanley boosted their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $60.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.